Stock listing

8EM Stock Price, News, Filings & Events — Editas Medicine, Inc.

Selected listing: 8EM · DUS · EUR · DE

This page tracks Editas Medicine, Inc.'s 8EM:DUS listing on DUS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 8EM:DUS. 8EM:DUS is the stock-level entry point for investors researching Editas Medicine, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. The company's market capitalization is approximately $399 million. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.

8EM:DUSEURDEUpdated September 11, 2026
Editas Medicine, Inc. logo
Ticker
8EM:DUS
Asset type
Stock
Market cap
$414.7M
Sector
Health Technology
Industry
Biotechnology
Exchange
DUS
Currency
EUR

Editas Medicine, Inc. 8EM:DUS stock context

This page tracks Editas Medicine, Inc.'s 8EM:DUS listing on DUS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 8EM:DUS. 8EM:DUS is the stock-level entry point for investors researching Editas Medicine, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. The company's market capitalization is approximately $399 million. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.

Latest news from Editas Medicine, Inc.

All Editas Medicine, Inc. news →

Editas Medicine, Inc. earnings calls

Research Editas Medicine, Inc.

Alternate listings